Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics, Inc. (NASDAQ: MYGN) generates frequent news as a molecular diagnostic testing and precision medicine company. Its announcements often cover financial results, clinical research, product updates, and collaborations that shape how genetic and genomic testing is used in oncology, women’s health, and mental health care.
Investors and clinicians following MYGN news will see regular earnings releases and financial guidance updates, which the company also furnishes on Form 8-K. These updates describe trends in hereditary cancer testing, tumor profiling, prenatal screening, and pharmacogenomics, along with commentary on business performance and strategic priorities.
Scientific and medical conference activity is another major source of news. Myriad Genetics frequently reports new data on tests such as the MyRisk Hereditary Cancer Test, Precise MRD, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, Foresight Carrier Screen, and the GeneSight Psychotropic test. Company communications highlight abstracts and posters at meetings like the San Antonio Breast Cancer Symposium and the National Society of Genetic Counselors Annual Conference.
News items also describe collaborations with partners including SOPHiA GENETICS, Clairity, and MagView, focused on areas such as liquid biopsy companion diagnostics and integrated breast cancer risk assessment platforms. Updates on leadership changes, credit facilities, and conference presentations at investor healthcare events are also part of the MYGN news flow.
This page provides a centralized view of these developments so readers can review Myriad Genetics’ latest financial disclosures, research milestones, product enhancements, and partnership announcements in one place.
Myriad Genetics (NASDAQ: MYGN) released select unaudited preliminary results for Q4 and full year 2025 and introduced full‑year 2026 guidance on Jan 12, 2026.
Preliminary revenue: Q4 2025 $207M–$209M; full year 2025 $822M–$824M. 2026 guidance: Revenue $860M–$880M, Adjusted Gross Margin 68%–69%, and Adjusted EBITDA $37M–$49M. The company will publish final audited results in February 2026 and host a webcast on Jan 14, 2026 at 5:15 pm PT.
Myriad Genetics (NASDAQ: MYGN) announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026 at 5:15 pm PT (8:15 pm ET). The presentation will be available via a live webcast and an archived replay at the company’s investor website: investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN) announced it will present 8 abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Dec. 10–11, 2025, covering MRD, germline testing, somatic profiling, and polygenic risk.
Key highlights include new data on the Precise Molecular Residual Disease (MRD) Test—a tumor-informed, WGS-based assay with custom selection of up to 1,000 variants and reported ultra-sensitivity at low tumor fractions (RUO)—and updates to the MyRisk Hereditary Cancer Test expanded to 63 genes. Myriad will sponsor a Product Theater session on Dec. 10 (2:30–3:30 p.m. CST) and host a booth (#1414) during exhibition hours.
Myriad Genetics (NASDAQ: MYGN), Clairity, and MagView announced a collaboration on Nov 25, 2025 to deliver the first integrated platform combining genotype and AI-derived phenotype for breast cancer risk assessment.
The integration links Myriad’s MyRisk with RiskScore hereditary cancer test, Clairity Breast (the FDA-authorized AI mammogram risk estimator), and MagView’s Luminary Risk workflow to provide clinicians a unified, actionable view of five-year breast cancer risk from routine mammograms and genetics.
The partners say the platform aims to identify more women at elevated risk and support earlier, personalized interventions while preserving clinical workflow efficiency.
Myriad Genetics (NASDAQ: MYGN) said its management will participate in two investor healthcare conferences in late 2025. Wolfe Research Healthcare Conference — fireside chat on Nov. 18, 2025 at 1:20 pm ET. Piper Sandler Healthcare Conference — fireside chat on Dec. 2, 2025 at 12:00 pm ET. Both presentations will be available via live audio webcasts in the investor information section at investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN) expanded its MyRisk® Hereditary Cancer Test on Nov 10, 2025 to include genes referenced in NCCN and ASCO guidelines.
The updated MyRisk panel now includes 63 genes covering more than 11 cancer types, and the company says it includes 100% of genes strongly recommended by national oncology guidelines to support treatment decisions, surveillance planning, and family risk assessment.
Results are available via paper requisition, the Myriad patient portal and multiple EMR platforms including EPIC.
Myriad Genetics (NASDAQ: MYGN) will present 11 new research studies at the National Society of Genetic Counselors 44th Annual Conference on Nov. 7–8, 2025, highlighting oncology and reproductive genetic testing advances.
Featured products include MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen. Myriad will exhibit at booth #317 and share poster presentations on topics such as RNA analysis for VUS interpretation, fetal fraction amplification for early cfDNA screening, prenatal cfDNA detecting maternal colorectal cancer, automated FXN repeat detection, and genetics education and recontact workflows.
Myriad Genetics (NASDAQ: MYGN) reported third quarter 2025 results: revenue $205.7M (down 4% YoY, flat ex‑$8.1M headwinds), gross margin 69.9%, GAAP net loss $27.4M (loss per share $0.29) and adjusted EPS $0.00. Third quarter adjusted EBITDA was $10.3M and test volumes rose to 386,000 (+3% YoY), led by hereditary cancer volume +11%.
The company entered a strategic collaboration with SOPHiA GENETICS for liquid biopsy CDx development, closed a $200M term loan in July, and ended the quarter with $145.4M cash. Myriad reiterated full‑year 2025 guidance: Revenue $818–$828M, gross margin 69.5%–70.0%, adjusted EBITDA $27–$33M, adjusted EPS $(0.02)–$0.02.
Myriad Genetics (NASDAQ: MYGN) reported a post-hoc analysis of the PRIME study showing GeneSight-informed treatment produced faster remission and response in major depressive disorder.
The PRIME trial enrolled 1,944 U.S. Veterans. The analysis, published Oct 30, 2025 in Frontiers in Pharmacology, found GeneSight patients were 27% more likely to achieve remission and 21% more likely to experience response at any time during the 24-week study, with benefits persisting through six months. Myriad plans to submit these data to payers to support access to GeneSight.
Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2025 financial results on November 3, 2025 after market close and will host an earnings conference call the same day at 4:30 PM ET. Management will provide a financial overview and business update for Q3 2025.
A live webcast will be available on Myriad’s Investor Relations website at investor.myriad.com. Telephone participants must register to receive a dial-in number and unique PIN. An archived webcast will be posted at investor.myriad.com following the call.